Global & United Kingdom Cancer Therapeutics Market to 2031

According to data from Macmillan Cancer Support, approximately 3 million individuals were living with cancer in the UK in 2020. This figure is expected to increase to 3.5 million by 2025 and reach 5.3 million by 2040.The emergence of immune checkpoint inhibitors has significantly transformed cancer treatment, offering renewed hope to patients. The UK also hosts Cancer Research UK, the world’s largest independent cancer charity. Each year, the organization allocates around £385 million (approximately US$488.76 million) to fund research efforts across numerous UK institutions. Through its extensive research initiatives, Cancer Research UK plays a pivotal role in improving outcomes for cancer patients and their families by advancing prevention, early detection, and treatment strategies.

Recent developments supported by the organization include the regulatory approval and national availability of two promising therapies—Akeega for prostate and breast cancer, and Truqap for hormone receptor-positive (HR-positive) breast cancer. These medications represent important progress in cancer care in the UK.

In October 2024, Innovate UK and the Office for Life Sciences (OLS) announced enhanced support for cancer-related innovation. Together, they plan to invest £4 million (around US$5.19 million) across six projects as part of their initiative to drive advancements in precision medicine. The OLS Cancer Programme aims to position the UK as a leading center for oncology innovation by accelerating the development and commercialization of next-generation cancer diagnostics and treatments.